Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
More News: Alli | Byetta | Cardiology | Cholesterol | Diabetes | Diets | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Fenofibrate | Heart | Heart Failure | High Fat | Hormones | Incretin Therapy | Insulin | Liver | Nutrition | Obesity | Physiology | Tricor | Urology & Nephrology | Xenical